Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678266 | 0.88 | HPGD (0.49) | SMN1; SMN2POLBNPC1RAB9AKDM4E | |
| SCHEMBL1677569 | 0.88 | NAAA (0.50) | SMN1; SMN2HTTNPC1RAB9AKDM4E | |
| SCHEMBL1678244 | 0.87 | HPGD (0.50) | SMN1; SMN2POLBNPC1RAB9AKDM4E | |
| SCHEMBL1677469 | 0.86 | NAAA (0.52) | SMN1; SMN2HTTNPC1RAB9AKDM4E | |
| SCHEMBL1678251 | 0.86 | NAAA (0.52) | SMN1; SMN2HTTNPC1RAB9AKDM4E | |
| SCHEMBL1677824 | 0.84 | NAAA (0.48) | SMN1; SMN2HTTNPC1RAB9AKDM4E | |
| SCHEMBL7723067 | 0.78 | HPGD (0.46) | SMN1; SMN2POLBNPC1RAB9AKDM4E | |
| SCHEMBL2185859 | 0.78 | KDM4E (0.44) | SMN1; SMN2POLBNPC1RAB9AKDM4E | |
| SCHEMBL1678459 | 0.77 | HSD11B1 (0.48) | POLBKDM4ECYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL2188170 | 0.77 | HPGD (0.44) | SMN1; SMN2HTTPOLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923461-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| EP-1568692-B1 | (Pyridinyl)alkyl-amides or -ureas as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20100016380-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1743885-B1 | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-7491739-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080182881-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-7345064-B2 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-03-18 | — | — | US | disclosed |
| EP-1743885-A2 | TNF-Alpha Produktion Hemmer zur Behandlung von Autoimmunerkrankungen | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-01-17 | — | — | EP | disclosed |
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| US-20060229342-A1 | TNF-a production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| US-7098226-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-08-29 | — | — | US | disclosed |
| EP-1568692-A1 | (pyridin-4-yl)alkyl-amides as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241155-A1 | 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes | TNFRSF1A, FFAR4, NGFR | ALOX12 216/4885SMN1; SMN2 4392/4885HTT 4571/4885 |
| US-20060229342-A1 | TNF-a production inhibitors | TNF, TNFRSF1A, TNFRSF9 | ALOX12 505/4885SMN1; SMN2 4499/4885HTT 4234/4885 |
| US-20080182881-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | ALOX12 579/4885SMN1; SMN2 4454/4885HTT 4451/4885 |
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | ALOX12 1370/4885SMN1; SMN2 4718/4885HTT 4594/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | ALOX12 1380/4885SMN1; SMN2 4717/4885HTT 4617/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | ALOX12 377/4885SMN1; SMN2 4171/4885HTT 4604/4885 |
| US-20100016380-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | ALOX12 1477/4885SMN1; SMN2 4681/4885HTT 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.